Teva Pharmaceutical Industries (TEVA) said, for 2026, non-GAAP operating income is now projected in a range of $3.80 - $4.0 billion, revised from $4.55 - $4.8 billion stand-alone outlook, impacted by an expected $700 million IPR&D charge and $75 million to reflect Emalex's operating expenses and transaction-related expenses. The company expects EPS in a range of $1.91 - $2.11, revised from prior Stand-Alone Outlook of $2.57 - $2.77. Adjusted EBITDA is projected in a range of $4.23 - $4.53 billion, updated from stand-alone guidance of $5.0 - $5.3 billion. Revenue guidance remains unchanged.
First quarter net income attributable to Teva were $369 million and $0.31 per share, compared to $214 million and $0.18 per share, a year ago. Non-GAAP net income attributable to Teva was $621 million and $0.53 per share compared to $602 million and $0.52 per share. Adjusted EBITDA was $1.055 billion, an increase of 1% from prior year. Revenues in the first quarter were $3.98 billion, an increase of 2% in U.S. dollars, or a decrease of 3% in local currency terms compared to the first quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.